Selected article for: "antiviral activity and host target"
Author: Ginex, Tiziana; Garaigorta, Urtzi; Ramírez, David; Castro, Victoria; Nozal, Vanesa; Maestro, Inés; García-Cárceles, Javier; Campillo, Nuria E.; Martinez, Ana; Gastaminza, Pablo; Gil, Carmen
Title: Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
  • Cord-id: ik9d5l8p
  • Document date: 2021_4_6
    • ID: ik9d5l8p
    Snippet: The unprecedent situation generated by the COVID-19 global emergency has prompted us to actively work to fight against this pandemic by searching for repurposable agents among FDA approved drugs to shed light into immediate opportunities for the treatment of COVID-19 patients. In the attempt to proceed toward a proper rationalization of the search for new antivirals among approved drugs, we carried out a hierarchical in silico/in vitro protocol which successfully combines virtual and biological
    Document: The unprecedent situation generated by the COVID-19 global emergency has prompted us to actively work to fight against this pandemic by searching for repurposable agents among FDA approved drugs to shed light into immediate opportunities for the treatment of COVID-19 patients. In the attempt to proceed toward a proper rationalization of the search for new antivirals among approved drugs, we carried out a hierarchical in silico/in vitro protocol which successfully combines virtual and biological screening to speed up the identification of host-directed therapies against COVID-19 in an effective way. To this end a multi-target virtual screening approach focused on host-based targets related to viral entry, followed by the experimental evaluation of the antiviral activity of selected compounds, has been carried out. As a result, five different potentially repurposable drugs interfering with viral entry—cepharantine, clofazimine, metergoline, imatinib and efloxate—have been identified.

    Search related documents:
    Co phrase search for related documents
    • active site and additional information: 1, 2
    • active site and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active site and low concentration: 1, 2
    • active site and low potency: 1, 2, 3, 4, 5
    • active site and luciferase activity: 1
    • acute sars cov respiratory syndrome coronavirus and additional information: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute sars cov respiratory syndrome coronavirus and local density: 1
    • acute sars cov respiratory syndrome coronavirus and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute sars cov respiratory syndrome coronavirus and low concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
    • acute sars cov respiratory syndrome coronavirus and low multiplicity: 1
    • acute sars cov respiratory syndrome coronavirus and low potency: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars cov respiratory syndrome coronavirus and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute sars cov respiratory syndrome coronavirus and luciferase assay system: 1
    • acute sars cov respiratory syndrome coronavirus and luciferase gene activity: 1
    • acute sars cov respiratory syndrome coronavirus and maestro suite: 1
    • additional information and low potency: 1
    • local density and low concentration: 1
    • low concentration and luciferase activity: 1
    • low concentration and luciferase gene activity: 1